Kristen Oelschlager Sells 12,218 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 12,218 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $33.69, for a total transaction of $411,624.42. Following the transaction, the chief operating officer owned 85,033 shares of the company’s stock, valued at approximately $2,864,761.77. This trade represents a 12.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Castle Biosciences Stock Up 0.5%

NASDAQ CSTL opened at $34.26 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. The company’s 50 day simple moving average is $26.99 and its 200 day simple moving average is $25.42. Castle Biosciences, Inc. has a 12 month low of $17.72 and a 12 month high of $44.28. The company has a market capitalization of $1.05 billion, a P/E ratio of -51.91 and a beta of 0.98.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.34. The business had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. Equities research analysts expect that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Advisors Capital Management LLC purchased a new stake in shares of Castle Biosciences in the second quarter worth approximately $5,681,000. Summit Partners Public Asset Management LLC grew its position in Castle Biosciences by 164.7% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after purchasing an additional 658,725 shares in the last quarter. SummitTX Capital L.P. grew its position in Castle Biosciences by 285.0% during the first quarter. SummitTX Capital L.P. now owns 67,033 shares of the company’s stock valued at $1,646,000 after purchasing an additional 49,623 shares in the last quarter. Quantinno Capital Management LP increased its stake in Castle Biosciences by 387.3% in the 1st quarter. Quantinno Capital Management LP now owns 45,476 shares of the company’s stock valued at $1,116,000 after buying an additional 36,144 shares during the period. Finally, AIGH Capital Management LLC acquired a new position in Castle Biosciences in the 2nd quarter valued at approximately $13,001,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. BTIG Research raised their price objective on Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. KeyCorp set a $35.00 target price on shares of Castle Biosciences in a report on Friday, May 29th. Zacks Research lowered shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. Robert W. Baird set a $36.00 price target on shares of Castle Biosciences in a research report on Friday, July 31st. Finally, Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Castle Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.